541 related articles for article (PubMed ID: 28323985)
1. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.
Kornaczewski Jackson ER; Pointon OP; Bohmer R; Burgess JR
J Clin Endocrinol Metab; 2017 Jun; 102(6):1926-1933. PubMed ID: 28323985
[TBL] [Abstract][Full Text] [Related]
2.
Satoh K; Sadowski SM; Dieckmann W; Quezado M; Nilubol N; Kebebew E; Patel D
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678
[TBL] [Abstract][Full Text] [Related]
3. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.
van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Kema IP; Koopmans KP; Valk GD; Timmers HJ; de Herder WW; Feelders RA; Fockens P; Sluiter WJ; de Vries EG; Links TP
Gastrointest Endosc; 2015 Jan; 81(1):159-167.e2. PubMed ID: 25527055
[TBL] [Abstract][Full Text] [Related]
4. An assessment of
So A; Pointon O; Hodgson R; Burgess J
Clin Endocrinol (Oxf); 2018 May; 88(5):683-691. PubMed ID: 29446832
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
[TBL] [Abstract][Full Text] [Related]
6. Clinical role of fludeoxyglucose (18F) positron emission tomography/computed tomography (
Matsumoto T; Okabe H; Yamashita YI; Yusa T; Itoyama R; Nakao Y; Yamao T; Umzaki N; Tsukamoto M; Kitano Y; Miyata T; Arima K; Nitta H; Hayashi H; Imai K; Chikamoto A; Baba H
Surg Today; 2019 Jan; 49(1):21-26. PubMed ID: 30128759
[TBL] [Abstract][Full Text] [Related]
7. The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (
Lung MS; Hicks RJ; Pavlakis N; Link E; Jefford M; Thomson B; Wyld DK; Liauw W; Akhurst T; Kuru N; Michael M
Asia Pac J Clin Oncol; 2020 Jun; 16(3):150-157. PubMed ID: 32030887
[TBL] [Abstract][Full Text] [Related]
8. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient.
Jullien M; Reichert T; D'Anella P; Castinetti F; Barlier A; Brue T; Taieb D; Cuny T
Ann Endocrinol (Paris); 2020 Feb; 81(1):39-43. PubMed ID: 31982106
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors.
Tomimaru Y; Eguchi H; Tatsumi M; Kim T; Hama N; Wada H; Kawamoto K; Kobayashi S; Morii E; Mori M; Doki Y; Nagano H
Surgery; 2015 Feb; 157(2):269-76. PubMed ID: 25311263
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease.
Kitano M; Millo C; Rahbari R; Herscovitch P; Gesuwan K; Webb RC; Venkatesan AM; Phan GQ; Hughes MS; Libutti SK; Nilubol N; Linehan WM; Kebebew E
Surgery; 2011 Dec; 150(6):1122-8. PubMed ID: 22136831
[TBL] [Abstract][Full Text] [Related]
12. What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?
Challis BG; Casey RT; Grossman A; Newell-Price J; Newey P; Thakker RV
Clin Endocrinol (Oxf); 2019 Dec; 91(6):708-715. PubMed ID: 31505044
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions.
Sadowski SM; Weisbrod AB; Ellis R; Patel D; Alimchandani M; Quezado M; Millo C; Venzon DJ; Nilubol N; Linehan WM; Kebebew E
J Am Coll Surg; 2014 May; 218(5):997-1003. PubMed ID: 24661849
[TBL] [Abstract][Full Text] [Related]
14. Growth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study.
Kappelle WF; Valk GD; Leenders M; Moons LM; Bogte A; Siersema PD; Vleggaar FP
Endoscopy; 2017 Jan; 49(1):27-34. PubMed ID: 27975336
[No Abstract] [Full Text] [Related]
15. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
16. Utility of FDG-PET imaging in screening for succinate dehydrogenase B and D mutation-related lesions.
Kornaczewski ER; Pointon OP; Burgess JR
Clin Endocrinol (Oxf); 2016 Aug; 85(2):172-9. PubMed ID: 26776272
[TBL] [Abstract][Full Text] [Related]
17. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.
Chiloiro S; Lanza F; Bianchi A; Schinzari G; Brizi MG; Giampietro A; Rufini V; Inzani F; Giordano A; Rindi G; Pontecorvi A; De Marinis L
Endocrine; 2018 May; 60(2):362-367. PubMed ID: 28567607
[TBL] [Abstract][Full Text] [Related]
19. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
[TBL] [Abstract][Full Text] [Related]
20. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).
Lastoria S; Marciello F; Faggiano A; Aloj L; Caracò C; Aurilio M; D'Ambrosio L; Di Gennaro F; Ramundo V; Camera L; De Luca L; Fonti R; Napolitano V; Colao A
Endocrine; 2016 Jun; 52(3):488-94. PubMed ID: 26242621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]